1995 Fiscal Year Final Research Report Summary
Development of orally administrable pertussis vaccine
| Project/Area Number |
06807027
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
YASUDA Yoko Nagoya City University, Medical School, Associate Professor, 医学部, 助教授 (70080009)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ICHIKAWA Yuko Nagoya City University, Medical School, Research Associate, 医学部, 助手 (80173441)
KOZUKA Satoshi Nagoya City University, Medical School, Research Associate, 医学部, 助手 (40117817)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Keywords | Oral vaccine / Cholera toxin B subunit / Mucosal adjuvant / Recombinant pertussis vaccine |
|---|
| Research Abstract |
One of the WHO programs for the year of 2,000 is "The Expanded Program on Immunization for Children". A new generation of children's vaccines that are inexpensive, orally administered, and effective against a dozen or more infectious diseases is reqiured, especially in developing countries.
We have succeeded high level production of recombinant cholera toxin B subunit (CTB) which acts as a mucosal adjuvant using the host-vector system of Bacillus brevis Udaka strain. We are developing mucosal vaccines in combination with the recombinant CTB for various infectious diseases. For pertussis vaccine development,
1. Recombinant B oligomer of pertussis toxin : High level production of the S2 subunit was succeeded, and that of other subunits S3, S4 and S5 is progressing.
2. Immune responses by orally administered pertussis vaccine : Commercially available perussis vaccine for injection was administered orally with recombinant CTB in BALB/c mice. The ELISA titers of serum IgG,intestinal IgA and lung lavage IgA against pertussis toxin, and those of serum IgG and intestinal IgA against filamentous hemmagglutinin were elevated, indicating that oral administration of the pertussis vaccine with recombinant CTB may be effective on humoral and local antibody responses to protect petussis.
|
